Synthetic cannabinoids sent 30 people to the ICU with life-threatening complications
A case series of 30 ICU patients found synthetic cannabinoid ingestion caused coma, seizures, acute respiratory failure, and one death, with standard drug tests unable to detect the substances.
Quick Facts
What This Study Found
Over two years, 30 patients were admitted to the ICU after synthetic cannabinoid use. Presenting diagnoses included coma (33%), agitation (33%), and seizures (20%). Seventy percent required intubation, 60% had acute respiratory failure, and 26% developed rhabdomyolysis. One patient died of ARDS. Standard toxicology screens were negative in 53% of cases.
Key Numbers
30 ICU patients; mean age 41; 80% male; 33% presented in coma; 70% required intubation; 60% had respiratory failure; 26% had rhabdomyolysis; 1 death; 53% had negative standard toxicology.
How They Did This
Retrospective case series of 30 adults admitted to ICU from 2014-2016 with confirmed or suspected synthetic cannabinoid ingestion, published in JAMA Network Open.
Why This Research Matters
Synthetic cannabinoids (K2, Spice) are far more dangerous than natural cannabis and are undetectable by standard drug tests. This series documents the severity of complications that can result, including death.
The Bigger Picture
The inability of standard drug tests to detect synthetic cannabinoids, combined with their severe toxicity profile, makes them a particularly dangerous public health threat. These products bear little pharmacological resemblance to natural cannabis despite being marketed as alternatives.
What This Study Doesn't Tell Us
Single-institution case series; no control group; retrospective data; many patients had polysubstance use histories; 53% left against medical advice, limiting follow-up.
Questions This Raises
- ?How can emergency departments better identify synthetic cannabinoid intoxication when standard tests fail?
- ?What specific compounds were involved in the most severe cases?
Trust & Context
- Key Stat:
- 70% required intubation; standard drug tests negative in 53%
- Evidence Grade:
- Moderate: published in JAMA Network Open with detailed clinical data, though limited by retrospective single-institution design.
- Study Age:
- Published 2020.
- Original Title:
- Critical Illness Secondary to Synthetic Cannabinoid Ingestion.
- Published In:
- JAMA network open, 3(7), e208516 (2020)
- Database ID:
- RTHC-02656
Evidence Hierarchy
Describes what happened to one person or a small group.
What do these levels mean? →Frequently Asked Questions
Can standard drug tests detect synthetic cannabinoids?
No. In this series, routine toxicology screening was negative in 53% of confirmed synthetic cannabinoid cases. Specialized testing is needed.
How dangerous are synthetic cannabinoids compared to natural cannabis?
Far more dangerous. This series documented coma, seizures, respiratory failure requiring intubation, and one death. Natural cannabis does not typically produce these life-threatening complications.
Read More on RethinkTHC
- 420-sober-survival-guide
- CBT-cannabis-recovery
- THC-purity-potency-label-meaning
- cannabis-relapse-cycle-pattern
- cold-turkey-vs-taper-quit-weed
- dab-concentrate-addiction-withdrawal
- dating-sober-after-quitting-weed
- delta-8-addiction-withdrawal
- edible-addiction-withdrawal-different
- edibles-psychosis-emergency-room
- exercise-quitting-weed-anxiety-brain
- grieving-quitting-weed-loss
- healthiest-way-to-consume-cannabis
- help-someone-quit-weed
- how-cannabis-products-made-concentrates-edibles
- how-to-quit-weed
- journaling-weed-withdrawal
- laced-weed-fentanyl-contaminated-vape
- legal-weed-vs-street-weed-quality-safety
- marijuana-anonymous-SMART-recovery-compare
- meditation-mindfulness-weed-withdrawal
- partner-still-smokes-weed
- partner-still-smokes-weed-quitting
- pink-cloud-sobriety-cannabis
- quit-weed-cold-turkey
- quit-weed-or-cut-back-which-is-better
- quit-weed-regret-went-back
- quitting-dabs-withdrawal
- quitting-edibles-withdrawal
- quitting-weed-20s
- quitting-weed-30s
- quitting-weed-after-years
- quitting-weed-during-crisis-divorce-job-loss
- quitting-weed-exercise
- quitting-weed-grief-loss-coping
- quitting-weed-legal-state
- quitting-weed-success-stories
- quitting-weed-triggers-environment
- relapsed-smoking-weed-what-to-do
- relapsed-weed
- sativa-vs-indica-difference-myth
- should-i-quit-weed
- sober-music-festival-concert-without-weed
- supplements-weed-withdrawal
- telling-friends-quitting-weed
- weed-potency-withdrawal
- weed-relapse-prevention-plan
- weed-relapse-why-it-happens
- weed-ritual-replacement
- weed-ruined-relationships
- weed-social-media-triggers-quit
Cite This Study
https://rethinkthc.com/research/RTHC-02656APA
Kourouni, Ismini; Mourad, Bashar; Khouli, Hassan; Shapiro, Janet M; Mathew, Joseph P. (2020). Critical Illness Secondary to Synthetic Cannabinoid Ingestion.. JAMA network open, 3(7), e208516. https://doi.org/10.1001/jamanetworkopen.2020.8516
MLA
Kourouni, Ismini, et al. "Critical Illness Secondary to Synthetic Cannabinoid Ingestion.." JAMA network open, 2020. https://doi.org/10.1001/jamanetworkopen.2020.8516
RethinkTHC
RethinkTHC Research Database. "Critical Illness Secondary to Synthetic Cannabinoid Ingestio..." RTHC-02656. Retrieved from https://rethinkthc.com/research/kourouni-2020-critical-illness-secondary-to
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.